dalteparin has been researched along with Respiratory Tract Diseases in 1 studies
Dalteparin: A low-molecular-weight fragment of heparin, prepared by nitrous acid depolymerization of porcine mucosal heparin. The mean molecular weight is 4000-6000 daltons. It is used therapeutically as an antithrombotic agent. (From Merck Index, 11th ed)
Respiratory Tract Diseases: Diseases involving the RESPIRATORY SYSTEM.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Kleber, FX | 1 |
| Witt, C | 1 |
| Vogel, G | 1 |
| Koppenhagen, K | 1 |
| Schomaker, U | 1 |
| Flosbach, CW | 1 |
1 trial available for dalteparin and Respiratory Tract Diseases
| Article | Year |
|---|---|
Randomized comparison of enoxaparin with unfractionated heparin for the prevention of venous thromboembolism in medical patients with heart failure or severe respiratory disease.
Topics: Aged; Anticoagulants; Drug Administration Schedule; Enoxaparin; Female; Heart Failure; Hemorrhage; H | 2003 |